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follow up
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Ana O Mocumbi, Martin Abanda, Friedrich Thienemann, Andre Pascal Kengne, Karen Sliwa
Abstract
Introduction: The epidemiology of pulmonary hypertension 
(PH) in low- to middle-income countries is poorly character-
ised. We assessed the prevalence, baseline characteristics and 
mortality rate in patients with echocardiographically diag-
nosed PH at a rural cardiac centre in Cameroon.
Methods: We conducted a prospective cohort study in a sub-
sample of 150 participants, aged 18 years and older, diag-
nosed with PH [defined as right ventricular systolic pressure 
(RVSP) ≥ 35 mmHg in the absence of pulmonary stenosis and 
right heart failure]. PH was classified as mild (RVSP: 35–50 
mmHg), moderate (RVSP: 51–60 mmHg) and severe (RVSP: 
> 60 mmHg).
Results: Of 2 194 patients screened via echocardiograms, 
343 (crude prevalence 15.6%) had PH. The sub-sample of 
150 patients followed up (54.7% women, mean age of 62.7 ± 
18.7 years) had a mean RVSP of 68.6 mmHg. They included 
7.3% mild, 29.3% moderate and 63.4% severe PH cases. 
Co-morbidities included log smoke (80.7%), hypertension  
(52.0%), family history of cardiovascular disease (50.0%), 
diabetes (31.3%), alcohol abuse (21.3%) and HIV infection 
(8.7%). Main clinical features were dyspnoea (78.7%), fatigue 
(76.7%), palpitations (57.3%), cough (56.7%), jugular venous 
distension (68%) and peripheral oedema (66.7%). Overall, 
70% presented in World Health Organisation functional 
class III/IV. PH due to left heart disease (PHLHD) was the 
commonest (64.7%), and rheumatic valvular disease account-
ed for 36.1%. The six-month mortality rate was 28%. 
Conclusion: PH, dominated by PHLHD, was common among 
adults attending this rural centre and was associated with 
a high mortality rate. Related co-morbidities and late clini-
cal presentation reflect the poor socio-economic context. 
Improved awareness of PH among physicians could promote 
early diagnosis and management.
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Pulmonary hypertension (PH) is defined as an increase in mean 
pulmonary arterial pressure (mPAP) at or above 25 mmHg at 
rest.1,2 It is currently classified by the World Health Organisation 
(WHO) into five subtypes, which include pulmonary arterial 
hypertension (PAH), PH due to left heart disease (PHLHD), 
PH due to lung disease or hypoxia (PHLDH), chronic 
thromboembolic PH (CTEPH) and PH due to unclear or 
multifactorial mechanisms (PHUM).3,4
The prevalence of  pulmonary vascular disease in the 
developing world is unknown, but estimates suggest that about 
25 million individuals may be affected.5 Little information exists 
on the epidemiology of PH in sub-Saharan Africa, however 
there is some evidence that based on the high prevalence of risk 
factors such as rheumatic heart disease, schistosomiasis and HIV 
infection in this area of the world, the prevalence and mortality 
rate of PH may be higher than in Western countries.6,7
In South Africa, PH has been identified as one of the 
commonest causes of death, accounting for 31% of total 
cardiovascular deaths,8 while only 8% of  cardiovascular 
deaths in the United Kingdom were attributed to PH in 2012.9 
Furthermore, studies from the United States have shown that 
the prevalence of PH among African Americans is higher than 
in Caucasians.10 These differences in the epidemiology of PH 
in different regions of the world are determined by genetic, 
geographic, environmental and socio-economic factors. 
Left heart disease has been widely suggested to be the 
most common cause of PH. In developing countries, chronic 
infectious diseases, hypertensive heart diseases, cardiomyopathy 
and rheumatic heart disease are the main contributors.6 This 
study aimed at determining the prevalence, baseline clinical 
characteristics and mortality rate during six months of follow up 
of patients with PH diagnosed via echocardiography at the rural 
Shisong Cardiac Centre (SCC) in Cameroon. 
Methods
This was a prospective cohort study in a sub-sample of 150 
participants aged 18 years and older who were diagnosed with PH 
via echocardiography. It was conducted at the Shisong Cardiac 
Centre from September 2013 to December 2014. This study also 
forms part of the Pan-African Pulmonary Hypertension Cohort 
study (PAPUCO). 
Shisong is a rural village in the Kumbo sub-division of the 
north-west region of Cameroon. Shisong, on the outskirts of 
Kumbo town, is about 400 km north of Douala, the economic 
capital of Cameroon, and 450 km north-west of Yaoundé, 
the political capital of  Cameroon.11 The Shisong Cardiac 
Centre (SCC) is a well-equipped centre for the diagnosis and 
management of a variety of cardio-surgical conditions including 
PH. On average 185 echocardiographic examinations are done 
per month. In this study, the target population was restricted 
to patients living in rural or sub-urban areas, aged 18 years and 
above, who underwent echocardiographic examination at the 
centre between September 2013 and December 2014.
The PAPUCO study design and procedures have been 
described in detail elsewhere.12 In brief, PH was diagnosed 
using echocardiography in patients with a right ventricular 
systolic pressure (RVSP) ≥ 35 mmHg in the absence of acute 
right heart failure (HF) and pulmonary stenosis. The data-
collection form, adapted from the PAPUCO study, was used 
to obtain patients’ information and clinical characteristics, 
including socio-demographic factors and past medical history 
[age, gender, body mass index (BMI), HIV status, family history 
of cardiovascular disease, systemic hypertension, dyslipidaemia, 
smoking and alcohol consumption], clinical presentation 
(dyspnoea, cough, fatigue, pedal oedema, palpitations and 
World Health Organisation functional classification). 
At six months post-baseline, patients and/or their next-of-kin 
were contacted by phone to determine their vital status. For all 
fatal outcomes, the probable cause of death was assessed through 
a verbal autopsy.
Statistical analysis
Data were analysed using SPSS® (Statistical Package for 
Social Sciences for Windows) version 20. Qualitative variables 
are summarised as frequencies and percentages. Continuous 
variables are represented as means and standard deviations, 
or median (25th to 75th percentiles). Patients were categorised 
in three groups depending on PH severity; mild if  RVSP was 
36–50 mmHg, moderate if  RVSP was 51– 60 mmHg and severe 
if  RVSP was > 60 mmHg. We used χ² to compare proportions 
and Student’s t-test or Kruskal–Wallis test to compare mean 
differences for continuous variables. Statistical significance was 
accepted at a p-value of 0.05.
Results
Out of a total of  2 194 patients who underwent cardiac 
echography at baseline, 343 had PH (prevalence rate 15.6%). 
Mean age was 61.9 ± 18.0 years and female gender (189, 55.1%) 
was predominant. As shown in Fig. 1, the peak prevalence of PH 
was noticed between 60 and 69 years (91/343, 26.5%).
Characteristics of the sub-sample followed up (n = 150) were 
similar to those of the overall PH group. The mean baseline age 
was 62.7 years [standard deviation (SD) =18.7]. Mean age did not 
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Fig. 1.  Age distribution of patients with pulmonary hyperten-
sion in the Shisong Cardiac Centre.
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 4, July/August 2018210 AFRICA
vary significantly by severity of PH (p = 0.25). Most participants 
(44.7%) had primary education, 32% had secondary education 
while 15.3% had never been to school. Variations by severity 
of PH were not significant (p = 0.69). The 150 followed-up 
participants included 11 (7.3%) with mild PH, 44 (29.3%) with 
moderate PH and 95 (63.4%) with severe PH. The proportion 
of women was 54.7% overall, and 5, 20 and 57%, respectively 
among the mild, moderate and severe PH groups (p = 0.09).
The distribution of risk factors for PH and co-morbidities are 
depicted in Fig. 2. Exposure to cooking fumes (80.7%), systemic 
hypertension (52.0%), family history of cardiovascular disease 
(50.0%), mitral valve regurgitation (49.3%), diabetes (31.3%) 
and alcohol abuse (21.3%) were the most common factors and 
co-morbidities identified in our study participants. 
Dyspnoea (78.7%), fatigue (76.7%), palpitation (57.3%) and 
non-productive cough (56.7%) were the main symptoms reported 
by patients on initial presentation. Syncope (6.7%) and cyanosis 
(6.0%) were rarely reported by our patients. Most patients who 
participated in this study had distended jugular veins (68.0%) 
and peripheral oedema (66.7%). Table 1 summarises variations 
in clinical signs and symptoms with PH severity. Chest pain 
varied significantly with PH severity (p = 0.03)
Fig. 3 shows variations of the World Health Organisation 
functional class (WHO FC) according to PH severity. More 
than half (53%) of the patients presented in WHO FC III, 28% 
presented in class II, while 17 and 2% presented in class IV and I, 
respectively. Therefore a greater proportion of patients presented 
with marked functional limitation. 
The main cause of PH was left heart disease (group 2), 
accounting for 64.7% of all cases, as shown in Fig. 4. In addition, 
15.3% was due to unclear or multifactorial aetiology (group 5), 
10% due to pulmonary arterial hypertension (group 1), 8% due 
to lung disease or hypoxia (group 3), and only 2% due to chronic 
thromboembolic mechanisms (group 4). Out of 97 participants 
with PHLHD, 50.5% had left ventricular systolic dysfunction 
(heart failure with reduced ejection fraction, HFrEF: EF ≤ 50%), 
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Fig. 2.  Risk factors and co-morbidities among 150 patients 
with pulmonary hypertension followed up at the 
Shisong Cardiac Centre.
Table 1. Clinical and echocardiographic findings of adult patients with PH 
Parameters All (n = 150) Mild PH (n = 11) Moderate PH (n = 44) Severe PH (n = 95) p-value
Clinical features at presentation
Difficulty breathing (dyspnoea), n (%) 118 (78.7) 9 (7.6) 32 (27.1) 77 (65.3) 0.32
Cyanosis, n (%) 9 (6.0) 1 (11.1) 2 (22.2) 6 (66.7) 0.58
Non-productive cough, n (%) 85 (56.7) 10 (11.8) 22 (25.9) 53 (62.3) 0.14
Fatigue, n (%) 115 (76.7) 8 (7.0) 30 (26.0) 77 (67.0) 0.10
Syncope, n (%) 10 (6.7) 0 3 (30.0) 7 (70.0) 0.33
Palpitations, n (%) 86 (57.3) 8 (9.3) 28 (32.6) 50 (58.1) 0.06
Chest pain, n (%) 49 (32.7) 6 (12.2) 17 (34.7) 26 (53.1) 0.03
Distended jugular veins, n (%) 102 (68.0) 8 (7.8) 26 (25.5) 68 (66.7) 0.22
Peripheral oedema, n (%) 100 (66.7) 9 (9.0) 25 (25.0) 66 (66.0) 0.43
NYHA I and II, n (%) 45 (30.0) 3 (6.0) 19 (42.2) 23 (51.1) 0.13
NYHA III and IV, n (%) 105 (70.0) 8 (7.6) 25 (23.8) 72 (68.6) 0.13
Vital signs 
BMI (kg/m2) 26.3 (18–46.8) 23.9 (21.2–26) 26.2 (18.6–42.4) 27.1 (18–46.8) 0.03
Systolic BP (mmHg) 126 (65–250) 133 (102–190) 123 (95–235) 127 (65–250) 0.26
Diastolic BP (mmHg) 79 (45–154) 73 (58–106) 78 (60–154) 80 (45–130) 0.73
Heart rate (beats/min) 88 (52–150) 96 (80–119) 88 (52–120) 86 (56–150) 0.43
Respiratory rate (breaths/min) 23 (13–40) 22 (19–28) 22 (13–35) 23 (15–40) 0.20
O2 saturation (%) 93 (55–100) 90 (82–98) 94.5 (67–99) 91.5 (55–100) 0.37
Echographic parameters
LVEDD (mm) 53 (16–72) 36 (18–56) 50 (38–70) 55 (16–72) 0.0001
LVESD (mm) 42 (13–60) 35 (13–43) 42 (22–60) 42 (18–97) 0.003
Ejection fraction (%) 48 (20–91) 66 (32–91) 46 (32–72) 46 (20–88) 0.06
Fractional shortening (%) 23 (6–95) 49 (28–61) 29 (18–33) 21 (6–95) 0.09
TAPSE (mm) 10 (7–25) 11 (8–20) 10 (8–17) 10 (7–25) 0.70
Data are number (%) or median (IQR).
BMI = body mass index, O2 = oxygen, LVEDD = left ventricular end-diastolic diameter, LVESD = left ventricular end-systolic diameter, TAPSE = tricuspid annular 
plane systolic excursion. 
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36.1% had valvular heart disease and 13.4% had left ventricular 
diastolic dysfunction (HFpEF: EF > 50%). 
The duration of follow up of the 150 participants ranged from 
five to 180 days. After a median follow up of 90.5 days, 42 deaths 
(cumulative mortality rate of 28%) were recorded. Equivalent 
figures were five deaths (cumulative incidence 45.5%) in mild PH, 
nine deaths (cumulative incidence 20.5%) in moderate PH and 
28 deaths (cumulative incidence 29.5%) in severe PH (p = 0.28).
Discussion
Our study aimed at determining the prevalence, clinical profile 
and mortality rate from PH in a rural setting in sub-Saharan 
Africa. We noted a high prevalence of PH, late presentation to 
healthcare facilities in an advanced state of heart failure, and 
consequently a high mortality rate at six months of follow up. 
These findings could be attributed to the poor socio-economic 
status, hyper-endemicity of risk factors for PH, and limited 
availability of PH-specific drug therapies. In the PAPUCO 
study,7 which was a multinational study on the epidemiology of 
PH in Africa with recruitment centres mostly in urban areas, 
similar findings were noted. Therefore it can be said that PH still 
presents a challenge on the African continent overall and not 
only in the rural setting.
Our observed prevalence of  15.6% is higher than the 
average of 10% prevalence observed in Australia in 2012 and 
in other European countries.13 This is somewhat to be expected 
considering the high burden of risk factors such as rheumatic 
heart disease, schistosomiasis, tuberculosis, sickle cell disease 
and HIV infection in sub-Saharan Africa, in addition to other 
risk factors shared with high-income countries. In addition, 
the SCC is located in a rural area that is difficult to access. 
Therefore, patients are usually reluctant to visit the centre 
until they are in advanced disease states or when referred by 
cardiologists. A recent expert review on the global perspective 
of the epidemiology of PH also supports our findings.6 Among 
the several co-morbidities assessed in our study population, 
exposure to cooking fumes was the most common, especially in 
women. This most likely results from the common practice in 
Africa and Cameroon, particularly in the rural setting, where 
women cook using open fires, unlike in high-income countries. 
Systemic arterial hypertension was also common and in line with 
studies from Africa,7 USA14,15 and Germany.16 
Hypertension is very common in sub-Saharan Africa where 
it affects about 30% of the adult population, and mostly goes 
undetected, undertreated and inadequately controlled.17 It is the 
principal cause of HF in sub-Saharan Africa. In the Pan-African 
THESUS-HF registry of HF for instance, it was estimated that up 
to 50% of HF cases were due to uncontrolled hypertension.18This 
high prevalence of uncontrolled hypertension would most likely 
also account for the high proportion of PHLHD in our study 
population. With the growing epidemic of HF, LHD is now 
globally recognised as the main cause of PH.6,7,13 PHLHD was 
dominated by patients with left ventricular systolic dysfunction, 
while PH due to rheumatic valvular heart disease is still common 
in our setting.
The clinical presentation was dominated by exertion 
dyspnoea, fatigue, cough and palpitations, which are common 
and non-specific symptoms in most patients with cardiovascular 
and/or respiratory conditions. Study participants were slightly 
overweight with a mean BMI higher than observed in a study 
in Nigeria,19 but lower than reported in the USA.15 Most of 
our participants presented with moderate to severe functional 
limitation, with 70% of them presenting in WHO FC or New 
York Heart Association (NYHA) class III and IV. 
These findings are similar to those in the PAPUCO study,7 and 
to those of Baptista and colleagues in Portugal in 2013,20 who 
observed that 71% of their patients presented in WHO FC III 
and IV, as well as those of Fikret and colleagues in Germany.16 
This global observation of late presentation to medical attention 
could be explained by the fact that most symptoms and signs of 
PH are non-specific and therefore cases are usually misdiagnosed 
in primary care until the later stages when patients seek specialist 
care. Furthermore, in Africa, poor access to healthcare, limited 
availability of diagnostic tools for PH, and the general reluctance 
of patients in rural settings to seek medical attention until the later 
stages of illness could explain at least in part the late presentation.
About a third of our patients died within the first six months 
of being diagnosed with PH. This mortality rate is three times 
higher than that observed in the USA15 and the UK.9 The high 
mortality rate in our setting is most likely accounted for to some 
extent by the unavailability of disease-specific drug therapies. 
The fact that patients present at an advanced stage of the disease, 
and their inability to comply with follow-up visits reflects to 
some extent their limited financial coping capacity, resulting in 
death in the absence of adequate care. 
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Limitations 
Our study has some limitations. Some cases of PH could have 
been missed because indications for cardiac echocardiography 
are usually symptom driven. This would lead to over-diagnosis 
of patients with severe disease, and accordingly, poor outcomes. 
Therefore whether our finding reflects those of  a typical 
population with PH in this setting is unknown. Diagnosis 
of PH in our study was done by echocardiography, which is 
more a screening tool for PH, while right heart catheterisation 
(RHC), which is the gold standard for diagnosing PH, was 
not used. Therefore, cases of mild PH could have been missed 
in our study. Furthermore the operator-dependent nature 
of echocardiography could lead to over- or under-diagnosis. 
Despite the fact that echocardiography is only a screening tool, 
it is paramount in the diagnosis of PH as it is non-invasive, 
more available and less expensive compared to RHC. Moreover, 
in expert hands, it yields reliable and reproducible results. 
Indeed, studies carried out to evaluate the diagnostic accuracy 
of echocardiography compared to RHC have demonstrated a 
sensitivity of 83% and a specificity of 72%.21 
Conclusion
Our findings suggest that PH is very common among patients 
attending our rural cardiac centre, with PHLHD being the most 
frequent type, and the short- to medium-term mortality rate 
being excessively high. Patients tend to present in advanced stages 
of disease and usually with several co-morbidities, most of which 
are cardiovascular conditions. Healthcare practitioners in this 
setting should be made more aware of this devastating condition, 
in order to prompt timely referral to specialised centres for proper 
evaluation and care of patients with suspected PH.
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Does the use of N-butyl-2 cyanoacrylate in the treatment 
of lower extremity superficial varicose veins cause acute 
systemic inflammation and allergic reactions?
Özge Korkmaz, Sabahattin Göksel, Müslim Gül, Hasan Başçil, Yavuz Yildir, Öcal Berkan
Abstract
Introduction: In this study we used N-butyl-2 cyanoacrylate 
(NBCA), including dimethyl sulfoxide (DMSO), via the 
endovenous route, for mechanochemical ablation in the treat-
ment of superficial venous insufficiency, in an attempt to 
establish whether an early systemic inflammatory response 
and an allergic reaction occurred in the patients.
Methods: A total of 102 patients were treated with endovenous 
medical ablation in two centres between October 2015 and 
February 2016. This study was a two-centre, retrospective, 
non-randomised investigational study. Ablation treatment 
with endovenous NBCA was used in patients with C3 to C4b 
grade superficial venous insufficiency, according to the CEAP 
(clinical, aetiology, anatomy and pathophysiology) clinical 
classification, with sapheno-femoral junctional insufficiency 
and a reflux of 0.5 seconds and longer on duplex ultra-
sonography. Pre-operative whole blood count, erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP) level and 
blood chemistry were studied in all patients on admission to 
the clinic, and repeated in the second hour post-intervention. 
Results: All patients were treated successfully. Pre-operative 
white blood cell count (WBC) was 6.82 ± 1.67 × 109 cells/μl, 
and post intervention it was 6.57 ± 1.49 × 109 cells/μl; the differ-
ence was not statistically significant (p = 0.68). The neutrophil 
count before the intervention was 4.09 ± 1.33 × 109 cells/μl, 
while afterwards, it was 4.09 ± 1.33 × 109 cells/μl, with no 
statistically significant difference (p = 0.833). Pre-intervention 
eosinophil count was 0.64 ± 1.51 × 109 cells/μl, while it was 
0.76 ± 1.65 × 109 cells/μl after the intervention, and the differ-
ence was statistically significant. Pre-intervention ESR and 
CRP values were 18.92 ± 9.77 mm/h and 1.71 ± 1.54 mg/dl, 
respectively. Postoperative ESR and CRP values were 19.78 ± 
15.90 mm/h and 1.73 ± 1.59 mg/dl, respectively, but the differ-
ences were not statistically significant. When the parameters 
were analysed by gender, the differences between pre- and 
postoperative WBC and eosinophil count, ESR and CRP in 
women were not statistically significant. On the other hand, 
although the change in WBC count and CRP value were not 
statistically significant in males, the differences in eosinophil 
count and ESR were statistically significant. 
Conclusion: Cyanoacrylate has been used in the endovenous 
medical ablation of varicose veins and superficial venous 
insufficiency over the last few years without the use of ther-
mal energy and tumescent anaesthesia, which represents 
the greatest advantage of this method. In addition, since it 
causes no systemic allergic or acute inflammatory reaction, it 
appears to be safe to use.
Keywords: N-butyl-2 cyanoacrylate, lower-extremity superficial 
varicous vein, acute systemic inflammation, allergic reaction
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Lower extremity venous insufficiency and the secondary 
development of varicose veins are important health problems 
that are frequently encountered in society. They impair the 
quality of life of individuals, and in certain conditions cause 
severe complications. The prevalence of venous insufficiency has 
been reported to be between 20 and 40% in many studies.1,2
Surgery has been the preferred method of treatment for this 
disease for more than 100 years. However, due to postoperative 
complications and frequent recurrence, alternative methods of 
treatment have been sought. Newly developed endovascular 
techniques have gradually replaced open surgery during the last 
two decades.
Haematoma, paresthesia, wound site scars, deformities, 
and a high rate of recurrence are among the complications 
of surgery.3,4 Minimally invasive endovenous thermo-ablation 
techniques (radiofrequency and laser), applied in the last decade 
in the treatment of superficial venous insufficiency and varicose 
veins, have decreased postoperative complications, shortened 
the healing process and improved quality of life.5 However, the 
necessity of tumescent anaesthesia during these techniques, 
and complications in the postoperative period, such as pain, 
ecchymosis and paresthesia caused by perforation of the vein 
wall, have limited the use of these techniques.6,7
The introduction of  cyanoacrylate (CA) in medical 
applications dates back to the 1960s. Surgeons used CA in order 
to stop bleeding and close wounds during the Vietnam War.8 
Also, endoscopic CA injection to stop gastric variceal bleeding 
has been safely and widely used.9 Recently, it has been used in the 
closure of type I and II endoleaks developing during the repair 
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of abdominal aortic aneurysms, varicoceles, pelvic congestion 
syndromes and arteriovenous malformations.10 
N-butyl-2 cyanoacrylate (NBCA) has been used via the 
endovenous route in the treatment of venous insufficiency 
and varicose veins, with the aim of biochemical ablation.11 
NBCA rapidly hardens in a polymerisation reaction following 
intravenous injection and occludes the vein. In addition, it causes 
a local inflammatory reaction in the vein wall and surrounding 
tissues.10,12 However, there are no studies in the literature evaluating 
whether NBCA causes systemic inflammation following contact 
with the blood circulation.
We attempted to establish whether NBCA caused a 
simultaneous systemic inflammatory response in the early period 
while causing a local inflammatory reaction in the vein wall and 
surrounding tissues in patients who were administered NBCA, 
including dimethyl sulfoxide (DMSO), for the treatment of 
superficial venous insufficiency. We retrospectively evaluated pre- 
and post-interventional blood samples in order to determine this.
Methods
This study was a two-centre, retrospective, non-randomised 
investigational study. Ablation treatment with endovenous 
NBCA was applied to patients with C3 to C4b grade venous 
insufficiency, according to the CEAP (clinical, aetiology, anatomy 
and pathophysiology) clinical classification, with sapheno-
femoral junctional insufficiency and a reflux of 0.5 seconds and 
longer on duplex ultrasonography, between October 2015 and 
February 2016. This treatment was abandoned in patients with a 
greater saphenous vein diameter of > 15 mm and < 5 mm. 
The treatment is contra-indicated in patients who have a 
past history of deep venous thrombosis, have femoral vein 
insufficiency, congenital vasculopathy, thrombophilia, the 
presence of  severe systemic disease, and in pregnant and 
lactating patients. This procedure was not used in any patient 
who had any of these conditions.
Detailed demographic data of the patients who were treated 
using endovenous NBCA ablation therapy were collected. Whole 
blood count, sedimentation rate, C-reactive protein (CRP) and 
blood chemistry were studied in all patients on admission to 
the clinic. These examinations were repeated in the second hour 
post-intervention.
Patients who were taken into the operating room to 
undergo endovascular medical ablation were monitored by the 
anaesthesiology team. Subsequently, both legs were re-evaluated 
with Doppler ultrasonography. The integrity of the iliac vein 
and inferior vena cava in the abdominal region was confirmed 
in order not to overlook some rare conditions, such as possible 
inferior vena cava agenesis.
Patients were placed in the supine position and the leg and 
inguinal region were cleaned and draped in order to perform 
the intervention under sterile conditions. With the aid of 
Doppler ultrasonography, an appropriate segment of the greater 
saphenous vein was selected for catheterisation, and a 5F 
introducer sheath was placed following local anaesthesia. The 
placement of the catheter was confirmed by ultrasonography. 
A 0.035-inch J guidewire was advanced into the sheath. 
Ultrasonography was used to determine whether the guidewire 
had reached the sapheno-femoral junction and a 4F carrier 
catheter was advanced into it. The catheter was confirmed to 
be at the sapheno-femoral junction and then withdrawn 3 mm, 
and a 3-ml syringe and piston system, which provides NBCA 
injection, was positioned. The location of the catheter was 
checked again by ultrasonography and it was confirmed not 
to be in the sapheno-femoral junction. The junction was then 
compressed by the ultrasonography probe and obstructed
The piston of the syringe administered 0.3 ml of NBCA 
during each pulse into the saphenous vein and compression 
was performed simultaneously. Intravenous administration of 
NCBA, which provided medical ablation, was continued while 
the catheter was withdrawn rapidly at a rate of 2 cm/s. At the 
end of the procedure, compression was continued for five to 10 
seconds and the procedure was terminated after the sapheno-
femoral junction was demonstrated by ultrasonography to be 
open and the rest of the greater saphenous vein was occluded. 
A compression sock was placed on the leg that underwent the 
procedure and medium pressure was applied. The patient was 
taken to the ward for follow up and repeat testing of the whole 
blood count, blood chemistry, CRP and sedimentation rate. 
Patients with no complications in the eighth hour postoperatively 
were discharged with a follow-up plan of visits on the 10th day, 
and one, three, six and 12 months postoperatively. 
Statistical analysis 
The results were evaluated using SPSS version 17. Changes in 
the patients’ values were calculated using the paired-samples 
t-test. The α-value was accepted as 0.05. The change in values 
by gender was calculated using the independent-samples t-test 
(p < α was accepted as significant). 
Results
A total of 102 patients were treated with endovenous medical 
ablation at two centres between October 2015 and February 
2016. The mean age of the patients was 51.16 ± 1.17 years (range: 
25–74); 72 (70.6%) were female and 30 (29.4%) were male. The 
mean diameter of the saphenous vein was 7.72 ± 2.02 mm (range: 
6–14). Among the general risk factors, a positive family history 
was present in 31 cases (30.3%), use of tobacco products in 17 
(16.7%), hypertension in six (5.9%), abnormal lipid profile in 19 
(18.7%), obesity in 24 (23.5%) and diabetes mellitus in five cases 
(4.9%) (Table 1).
Table 1. Demographics of the patients
Demographic data Number (%)
Age (years) 51.16 ± 1.17 
Gender (female/male) 72 (70.6)/30 (29.4)
Presence of family history 31 (30.3)
Use of tobacco products 17 (16.7)
Hypertension 6 (5.9)
Abnormal lipid profile 19 (18.7)
Obesity (BMI ≥ 30 kg/m2) 24 (23.5)
Diabetes mellitus 5 (4.9)
CEAP classification 
C3 42 (41.2)
C4a 37 (36.3)
C4b 23 (22.5)
Vein diameter (mm) 7.72 ± 2.02
BMI: body mass index; CEAP: clinical, aetiology, anatomy and pathophysiology.
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When the distribution of CEAP classification was analysed, 
42 (41.2%) patients were found to be C3 grade, 37 (36.3%) 
were C4a, and 23 (22.5%) were C4b. All patients were treated 
successfully. Pre-operative white blood cell count (WBC) was 
6.82 ± 1.67× 109 cells/μl, while after the intervention it was 6.57 ± 
1.49 × 109 cells/μl; the difference was not statistically significant 
(p = 0.68). The neutrophil count before the intervention was 4.09 
± 1.33 × 109 cells/μl, and post intervention it was 4.09 ± 1.33× 
109 cells/μl, with no statistically significant difference (p = 0.833). 
The eosinophil count was 0.64 ± 1.51 × 109 cells/μl prior to the 
procedure, and after the procedure it was 0.76 ± 1.65 × 109 cells/
μl. The difference was statistically significant, demonstrating a 
negative correlation (p = 0.01) (Table 2). 
Pre-intervention sedimentation rate and CRP values were 
18.92 ± 9.77 mm/h and 1.71 ± 1.54 mg/dl, respectively, and 
postoperative values were 19.78 ± 15.90 mm/h and 1.73 ± 
1.59 mg/dl, respectively. The differences were not statistically 
significant (psedim = 0.480, pCRP = 0.714). The change in values pre- 
and post intervention are presented in detail in Table 2. 
The change in values by gender are summarised in Table 3. 
Differences in pre- and postoperative WBC and eosinophil count, 
sedimentation rate and CRP were not statistically significant in 
women. On the other hand, although the change in WBC count 
and CRP value was not statistically significantly different in 
males, the difference in the eosinophil count was statistically 
significant, with a negative correlation (p = 0.002). The difference 
in sedimentation rate was also statistically significant and 
demonstrated a positive correlation (p = 0.005) (Table 3). In 
other words, postoperative sedimentation rate decreased in men 
and the change was 2.66 ± 4.76 mm/h, which was statistically 
significantly different (p < 0.05) (Table 3). When the difference in 
the rheumatoid factor was evaluated pre- and postintervention, 
no statistically significant changes were found in either gender (p 
< 0.05) (Table 3).
Discussion
The field of use of cyanoacrylate (CA) in medical treatment 
has gradually increased since its discovery.13,14 It has been used 
in ophthalmological operations, cosmetic procedures, dental 
applications and acute bleeding, with the aim of stopping the 
bleeding and attaching the tissues. Also, endoscopic injection 
of CA has been widely and safely used in order to cease gastric 
variceal bleeding.9 Recently it has been administered via the 
endovenous route for the treatment of varicose veins and 
superficial venous insufficiency without the need for tumescent 
anaesthesia11 or thermal energy, with increasing evidence proving 
that it could be an appropriate agent for the treatment of 
peripheral varicose veins.10,15  
The mechanism of effect of NBCA is simple; it stimulates 
polymerisation when it comes into contact with blood and 
plasma, hence causing an obstruction of the vein in which it 
is administered. This occurs in three steps: the initiation phase 
lasts approximately 10 seconds and the tensile force increases 
rapidly; the second phase lasts for approximately one minute and 
creates a steady tensile force; the last phase is completion of the 
polymerisation and a strong tensile force is obtained.16 
Almeida et al. closed the truncal vein of pigs using CA 
and after a follow-up period of 60 days, found no thrombus 
obstructing the lumen of the vein on sonography or histology. 
Instead he observed a chronic foreign body reaction against 
NBCA.15 When the tissues were examined, they observed an 
inflammatory reaction and the formation of giant cell foreign 
bodies, followed by the development of intraluminal fibrosis.15 
Endovenous NBCA application has been well tolerated in 
Table 3. Pre- and postoperative changes in whole blood and 
serological parameters by gender
Parameter
Pre-operative 
value 
Postoperative 
value t-value p-value
WBC (× 103 cells/μl)
Female 6.87 ± 1.55 6.65 ± 1.53 1.375 0.173
Male 6.68 ± 1.96 6.37 ± 1.41 1.262 0.217
Neutrophils (× 103 cells/μl)
Female 3.99 ± 1.30 3.99 ± 1.30 –0.985 0.328
Male 4.35 ± 1.39 4.34 ± 1.38 1.116 0.273
Eosinophils (× 103 cells/μl)
Female 0.51 ± 1.03 0.51 ± 0.98 0.000
Male 0.96 ± 2.28 1.37 ± 2.57 –3.479 1.000
Basophils (× 103 cells/μl) 0.002*
Female 0.06 ± 0.16 0.04 ± 0.07 1.199 0.235
Male 0.33 ± 0.74 0.09 ± 0.22 1.740 0.093
Haemoglobin (g/dl)
Female 13.17 ± 0.93 13.05 ± 0.89 1.000 0.324
Male 15.26 ± 1.51 15.76 ± 1.32 –2.584 0.022*
Haematocrit (%)
Female 40.64 ± 2.77 39.78 ± 2.76 1.837 0.075
Male 45.29 ± 4.08 49.16 ± 9.74 –1.650 0.121
Thrombocytes (103 cells/μl)
Female 260.80 ± 61.55 239.31 ± 88.02 1.551 0.129
Male 186.11 ± 33.16 193.72 ± 38.98 –2.061 0.055
Sedimentation rate (mm/h)
Female 22.08 ± 9.42 24.41 ± 16.79 –1.407 0.164
Male 11.33 ± 5.54 8.66 ± 3.07 3.065 0.005*
CRP (mg/dl)
Female 1.24 ± 1.25 1.30 ± 1.26 –1.540 0.128
Male 2.84 ± 1.62 2.75 ± 1.85 0.526 0.603
Rheumatoid factor (IU/ml)
Female 6.80 ± 5.83 6.41 ± 5.63 0.853 0.396
Male 7.11 ± 4.79 7.24 ± 2.50 –0.205 0.839
WBC: white blood cells; CRP: C-reactive protein.
Table 2. Pre- and postoperative changes in whole blood  
and serological parameters of patients
Parameter
Pre-operative 
value 
Postoperative 
value
Amount of 
change t-value p-value
WBC  
(× 103 cells/μl)
6.82 ± 1.67 6.57 ± 1.49 0.24 ± 1.33 1.846 0.068
Neutrophils  
(× 103 cells/μl)
4.09 ± 1.33 4.09 ± 1.33 –0.00 ± 0.02 0.211 0.833
Eosinophils  
(× 103 cells/μl)
0.64 ± 1.51 0.76 ± 1.65 –0.11 ± 0.46 –2.624 0.010*
Basophils  
(× 103 cells/μl)
0.14 ± 0.43 0.06 ± 0.13 0.08 ± 0.42 1.966 0.052
Haemoglobin  
(g/dl)
13.79 ± 1.47 13.84 ± 1.61 –0.05 ± 0.80 –0.503 0.617
Haematocrit 
(%)
42.00 ± 3.82 42.54 ± 7.11 –0.53 ± 5.78 –0.656 0.515
Platelets  
(× 103 cells/μl)
238.01 ± 64.33 225.40 ± 78.97 12.61 ± 75.39 1.285 0.204
Sedimentation  
(mm/h)
18.92 ± 9.77 19.78 ± 15.90 –0.86 ± 12.29 –0.709 0.480
CRP (mg/dl) 1.71 ± 1.54 1.73 ± 1.59 –0.21 ± 0.59 –0.634 0.714
Rheumatoid 
factor (IU/ml)
6.89 ± 5.52 6.65 ± 4.92 0.23 ± 3.80 0.634 0.527
WBC: white blood cells; CRP: C-reactive protein. *p < 0.05 statistically significant.
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patients. The results of our administration are similar. 
Inflammation is activated when an organism is triggered by 
stimulants. An acute inflammatory reaction is characterised by 
neutrophil predominance in the region of the event.17 Neutrophil 
and leukocyte counts in the blood are increased during acute 
inflammation. No statistically significant changes were detected 
between pre- and postoperative counts of either WBC or 
neutrophils in our study. Acute inflammation in the endovenous 
administration of NBCA was therefore most likely localised 
in the vein wall and surrounding tissues. There are reports 
in the literature demonstrating that NBCA causes a local 
inflammation,10,12 but there are no studies that have evaluated the 
systemic response. 
The acute-phase response includes endocrinological, 
neurological and immunological events.18 Proteins, whose levels 
increase or decrease during this period, are called acute-phase 
proteins or acute-phase reactants.19 Change in the levels of 
acute-phase proteins demonstrate the presence and severity of 
inflammation.20 
Cytokines are released as a response to stress by inflammatory 
cells such as neutrophils and macrophages. Interleukine-6, 
interleukine-1 and tumour necrosis factor-α induce CRP 
secretion from the hepatocytes.21 CRP has a pro- and anti-
inflammatory effect. Its pro-inflammatory effects result in the 
activation of the complement system and the induction of tissue 
factor and inflammatory cytokines from the monocytes, but its 
most important role is its anti-inflammatory effect.22 
Erythrocyte sedimentation rate (ESR) is a frequently used 
test for the evaluation of acute-phase response.23 ESR increases 
from the start of the inflammation and resolution may take up 
to a month.24 In our study, no statistically significant change was 
seen in the CRP level and sedimentation rate between the pre- 
and post-procedure states of endovenous NBCA use. Changes 
in sedimentation rate from the pre- to the postoperative values 
by gender were statistically significant in the male patients 
(p < 0.05); however they were within the normal range, and 
postoperatively showed a decreasing trend. CRP levels were 
similar between the pre- and post-procedural states by gender 
and in the overall group of patients. Since there was no change 
demonstrated in the CRP level and sedimentation rate, and in the 
neutrophil and WBC counts, it can be concluded that NBCA did 
not cause an acute systemic inflammatory response. 
Sensitivity has been detected in patients when NBCA was 
used to repair skin wounds, and also in individuals who 
were occupationally exposed to CA.25 In a study by Quinn 
et al., eosinophilic inflammation was detected at a rate of 
approximately 2% following NBCA use in the closure of 
intracranial arteriovenous malformations. The authors reported 
that no history of sensitivity against or exposure to CA was 
previously detected in those patients.25 When our patients was 
evaluated, no statistically significant changes in the pre- and 
postoperative eosinophil and basophil counts were found. From 
these results, we concluded that NBCA caused no allergic 
reaction in this patient group. 
Conclusion
The greatest advantage of the endovenous medical ablation 
method using NBCA is that tumescent anaesthesia and thermal 
energy are not necessary. In addition, since it causes no systemic 
allergic or acute inflammatory reaction, it appears safe to use. 
However, we suggest that evaluations should be performed in a 
larger group of patients to confirm the results. 
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Significant financial stress associated with 13-fold higher odds of having a heart attack
Significant financial stress is associated with a 13-fold 
higher odds of having a heart attack, according to research 
presented at the 18th Annual Congress of the South African 
Heart Association.
‘The role of psychosocial factors in causing disease is a 
neglected area of study in South Africa, perhaps because 
there are so many other pressing health challenges such 
as tuberculosis and HIV,’ said lead author Dr Denishan 
Govender, associate lecturer, University of the Witwatersrand, 
Johannesburg.
‘The INTERHEART study showed that psychosocial 
factors are independently associated with acute myocardial 
infarction (heart attack) in Africa but as far as we are aware 
there are no other published local data,’ said last author 
Professor Pravin Manga, professor of cardiology, University 
of the Witwatersrand.
This study included 106 patients with acute myocardial 
infarction who presented to a large public hospital in 
Johannesburg. A control group of 106 patients without 
cardiac disease was matched for age, gender and race. All 
participants completed a questionnaire about depression, 
anxiety, stress, work stress and financial stress in the previous 
month. The Likert scale was used to grade the experience of 
each condition.
Regarding financial stress, patients were graded with no 
financial stress if  they were coping financially; mild financial 
stress if  they were coping financially but needed added 
support; moderate financial stress if  they had an income 
but were in financial distress; and significant financial stress 
if  they had no income and at times struggled to meet basic 
needs. Levels of psychosocial conditions were compared 
between groups and used to calculate associations with 
having a heart attack.
Self-reported stress levels were common, with 96% of 
heart attack patients reporting any level of stress, and 40% 
reporting severe stress levels. There was a three-fold increased 
risk of myocardial infarction if  a patient had experienced 
any level of depression (from mild to extremely severe) in the 
previous month compared to those with no depression.
Both work stress and financial stress were associated 
with a higher risk of acute myocardial infarction. The odds 
of myocardial infarction was 5.6 times higher in patients 
with moderate or severe work stress compared to those with 
minimal or no stress. Patients with significant financial stress 
had a 13-fold higher odds of having a myocardial infarction.
Dr Govender said: ‘Our study suggests that psychosocial 
aspects are important risk factors for acute myocardial 
infarction. Often patients are counselled about stress after 
a heart attack but there needs to be more emphasis prior to 
an event. Few doctors ask about stress, depression or anxiety 
during a general physical and this should become routine 
practice, like asking about smoking. Just as we provide advice 
on how to quit smoking, patients need information on how 
to fight stress.’
Professor Manga said: ‘There is growing recognition that 
many developing countries are experiencing an increasing 
prevalence of chronic diseases of lifestyle such as myocardial 
infarction, and South Africa is no exception. Our study 
shows that psychosocial aspects are an area of cardiovascular 
prevention that deserves more attention.’
Dr David Jankelow, chairman of the SA Heart 2017 
congress, commented: ‘We know that the depressed cardiac 
patient is at greater risk. We as clinicians need to identify 
them much earlier, so that they can be referred for appropriate 
intervention. Cardiac rehabilitation together with counselling 
and reassurance will play an important role as well.’
Professor Fausto Pinto, ESC immediate past president and 
course director of the ESC programme in South Africa, said: 
‘Psychosocial factors including stress at work, depression and 
anxiety contribute to the risk of developing cardiovascular 
disease and having a worse prognosis. European prevention 
guidelines say that psychosocial risk-factor assessment 
should be considered in people with, or at high risk of, 
cardiovascular disease to identify possible barriers to lifestyle 
change or adherence to medication.’
Source: European Society of Cardiology Press Office
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